Skip to main
LRMR

LRMR Stock Forecast & Price Target

LRMR Analyst Ratings

Based on 7 analyst ratings
Buy
Strong Buy 43%
Buy 57%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Larimar Therapeutics has demonstrated promising clinical outcomes with its lead product candidate, CTI-1601, as indicated by a significant increase in median frataxin (FXN) expression from 2.7 pg/ug at baseline to 13.44 pg/ug at six months, exceeding the levels seen in over 50% of healthy volunteers. Additionally, the company reported a median improvement of -2.20 points in the Modified Friedreich's Ataxia Rating Scale (mFARS), contrasting with a decline for the FACOMS natural history population, further supporting the efficacy of its treatment. These positive clinical data metrics highlight the potential for CTI-1601 to address critical therapeutic needs in patients with Friedreich's ataxia, reinforcing a favorable outlook for the company’s stock.

Bears say

Larimar Therapeutics has faced a substantial decrease in its revenue projections for fiscal year 2029, with estimates dropping from $659 million to $407 million, raising concerns about the company’s growth potential in the Friedreich's ataxia market. Additionally, the median mFARS score change of -2.20 points over one year suggests underwhelming therapeutic performance compared to the FACOMS data, which recorded a +1.00 point change, indicating potential difficulties in demonstrating clinical efficacy. These factors contribute to a negative outlook on the company's financial health and market confidence in its lead product candidate, CTI-1601.

LRMR has been analyzed by 7 analysts, with a consensus rating of Buy. 43% of analysts recommend a Strong Buy, 57% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Larimar Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Larimar Therapeutics Inc (LRMR) Forecast

Analysts have given LRMR a Buy based on their latest research and market trends.

According to 7 analysts, LRMR has a Buy consensus rating as of Jan 13, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $16.71, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $16.71, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Larimar Therapeutics Inc (LRMR)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.